Advertisement

Topics

Aspreva Pharmaceuticals Corporation Company Profile

02:56 EDT 21st June 2018 | BioPortfolio

We are a team of highly motivated, talented and passionate individuals who share the vision of changing the treatment landscape for patients living with a less common disease. Aspreva's vision Aspreva's vision is to change the treatment landscape for people living with less common diseases by increasing the pool of evidence-based medicines available for these patients. What we do Aspreva is focused on addressing the needs of individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. Aspreva uses a proprietary screening program to identify late stage and approved medicines that show potential for high therapeutic impact in less common diseases. We then partner with pharmaceutical and biopharmaceutical companies to acquire the rights to develop the drug in these new indications, including clinical research and regulatory approvals. Once approved, we apply a strategic and specialized approach to commercializing products for these complex therapeutic categories. Our expertise lies in the clinical, regulatory and commercial development of products for complex diseases and specialized patient populations which differs significantly from traditional pharmaceutical activities. Aspreva is a leader in this new era of pharmaceutical partnering. For more information about our partnerships, please visit the Partners page. For information on our current research, please visit Clinical Trials. Why we do it Aspreva is driven by a desire to enrich the lives of millions of patients worldwide who are affected by less common diseases. We believe we can make a valuable contribution to the management of these diseases by delivering effective, evidence-based treatments. Our partnering strategy enables pharmaceutical and biopharmaceutical companies to develop their drugs, clinically and commercially outside of their products' strategic focus. It is the strength of our partnerships that deliver real benefit to our patients.

Location

#1203,4464 Markham Street
Victoria
V8Z7X8
Canada

Contact

Phone: 1 250 744-2488
Fax: 1 250 744-2498
Email: info@aspreva.com


News Articles [583 Associated News Articles listed on BioPortfolio]

Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018

ORION CORPORATION         STOCK EXCHANGE RELEASE         1 MARCH 2018   at 19.10 EET             Orion Corporation: Transfer of ...

Orion Corporation: Managers' transactions - Ari Lehtoranta

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Ari Lehtoranta Orion Corporation has received the...

Orion Corporation: Managers' transactions - Liisa Hurme

ORION CORPORATION         MANAGERS' TRANSACTIONS 2nd of March 2018 at 9.45 EET Orion Corporation: Managers' transactions - Liisa Hurme Orion Corporation has received...

Orion Corporation: Managers' transactions - Timo Maasilta

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Timo Maasilta Orion Corporation has received the ...

Orion Corporation: Managers' transactions - Eija Ronkainen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST Orion Corporation: Managers' transactions - Eija Ronkainen Orion Corporation has received...

Orion Corporation: Managers' transactions - Sirpa Jalkanen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EETS Orion Corporation: Managers' transactions - Sirpa Jalkanen Orion Corporation has received the ...

Orion Corporation: Managers' transactions - Mikael Silvennoinen

ORION CORPORATION         MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST              Orion Corporation: Managers' transactions - Mikael Silvennoinen Orio...

Orion Corporation: Managers' transactions - Heikki Westerlund

ORION CORPORATION      MANAGERS' TRANSACTIONS 3 MAY 2018 at 11.40 EEST              Orion Corporation: Managers' transactions - Heikki Westerlund Orion Co...

PubMed Articles [133 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Environmental concentrations of pharmaceuticals directly affect phytoplankton and effects propagate through trophic interactions.

Pharmaceuticals are found in freshwater ecosystems where even low concentrations in the range of ng Lmay affect aquatic organisms. In the current study, we investigated the effects of chronic exposure...

Clinical Trials [216 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1496 Associated Companies listed on BioPortfolio]

Aspreva Pharmaceuticals Corporation

We are a team of highly motivated, talented and passionate individuals who share the vision of changing the treatment landscape for patients living with a less common disease. Aspreva's vision Asprev...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, brand...

RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi plat...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

More Information about "Aspreva Pharmaceuticals Corporation" on BioPortfolio

We have published hundreds of Aspreva Pharmaceuticals Corporation news stories on BioPortfolio along with dozens of Aspreva Pharmaceuticals Corporation Clinical Trials and PubMed Articles about Aspreva Pharmaceuticals Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aspreva Pharmaceuticals Corporation Companies in our database. You can also find out about relevant Aspreva Pharmaceuticals Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record